Bifogade filer
PDF
Kurs
-2,38%
Likviditet
0,63 MSEK
Kalender
| Tid* | ||
| 2025-06-03 | 07:00 | Bokslutskommuniké 2025 |
| 2025-03-03 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-01-20 | N/A | Extra Bolagsstämma 2025 |
| 2024-12-04 | - | Kvartalsrapport 2025-Q2 |
| 2024-09-26 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2024-09-25 | - | Årsstämma |
| 2024-08-29 | - | Kvartalsrapport 2025-Q1 |
| 2024-05-30 | - | Bokslutskommuniké 2024 |
| 2024-02-29 | - | Kvartalsrapport 2024-Q3 |
| 2023-12-04 | - | Kvartalsrapport 2024-Q2 |
| 2023-10-04 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2023-09-27 | - | Årsstämma |
| 2023-08-31 | - | Kvartalsrapport 2024-Q1 |
| 2023-06-08 | - | Bokslutskommuniké 2023 |
| 2023-03-01 | - | Kvartalsrapport 2023-Q3 |
| 2022-12-01 | - | Kvartalsrapport 2023-Q2 |
| 2022-10-03 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2022-09-28 | - | Årsstämma |
| 2022-08-31 | - | Kvartalsrapport 2023-Q1 |
| 2022-06-10 | - | Bokslutskommuniké 2022 |
| 2022-03-02 | - | Kvartalsrapport 2022-Q3 |
| 2021-12-02 | - | Kvartalsrapport 2022-Q2 |
| 2021-09-09 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2021-09-02 | - | Kvartalsrapport 2022-Q1 |
| 2021-05-31 | - | Bokslutskommuniké 2021 |
| 2021-03-03 | - | Kvartalsrapport 2021-Q3 |
| 2020-12-02 | - | Kvartalsrapport 2021-Q2 |
| 2020-09-30 | - | Årsstämma |
| 2020-09-09 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2020-08-24 | - | Kvartalsrapport 2021-Q1 |
| 2020-06-08 | - | Bokslutskommuniké 2020 |
| 2020-04-20 | - | Extra Bolagsstämma 2020 |
| 2020-03-02 | - | Kvartalsrapport 2020-Q3 |
| 2019-12-02 | - | Kvartalsrapport 2020-Q2 |
| 2019-09-30 | - | Årsstämma |
| 2019-09-25 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2019-09-02 | - | Kvartalsrapport 2020-Q1 |
| 2019-06-10 | - | Bokslutskommuniké 2019 |
| 2019-03-04 | - | Kvartalsrapport 2019-Q3 |
| 2018-12-17 | - | Kvartalsrapport 2019-Q2 |
| 2018-09-25 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2018-09-24 | - | Årsstämma |
| 2018-09-24 | - | Kvartalsrapport 2019-Q1 |
| 2018-06-25 | - | Bokslutskommuniké 2018 |
| 2018-03-26 | - | Kvartalsrapport 2018-Q3 |
| 2017-12-18 | - | Kvartalsrapport 2018-Q2 |
| 2017-09-25 | - | Årsstämma |
| 2017-09-25 | - | Kvartalsrapport 2018-Q1 |
| 2017-06-30 | - | Bokslutskommuniké 2017 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Mölndal, Sweden, May 2[nd], 2022 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that Hannover Medical School has expanded its treatment arsenal and implemented OPRA[TM] Implant System in clinical use. The first surgeries with the technique have successfully been completed and the hospital will continue to offer the treatment to suitable patients with above-knee, arm, and digit amputations.
Hannover Medical School is the hospital that has tradition with osseointegration in Germany. In October 2022 the new chief of the trauma department - Prof. Stephan Sehmisch- established a new division for Innovations in Amputee Medicine for the best care of amputees. Since December 2021, the hospital has offered Integrum's OPRA™ Implant System. Two patients, one arm amputee and one leg amputee, have successfully been treated so far.
"Integrum's OPRA™ Implant System is a much-welcomed complement to our treatment arsenal. With the OPRA™ Implant System, we now have further options to offer our amputees, and I look forward to also being able to treat patients with arm or digit amputations. This innovative implant system will help many of our patients back to an active life," says Dr. Jennifer Ernst, the surgeon performing the first procedures at Hannover Medical School.
Hannover Medical School is the latest among several new hospitals to offer Integrum's OPRA™ Implant System in Germany.
"We are delighted to learn about yet another successful clinical implementation of our advanced bone-anchored implants. It is a great acknowledgment of our implant system that Hannover Medical School now chooses to expand their established treatment arsenal and implement our products in clinical use," comments María López, Integrum's CEO.
Integrum's OPRA[TM] Implant System is a bone-anchored system based on osseointegration. As the prostheses are directly attached to the bone, the use of a socket is avoided, leading to fewer complications and better quality of life for the patient.
María López, CEO. +46 (0) 70 846 10 69, E-mail: maria.lopez@integrum.se
Dennis Baecklund, CFO. Phone: +46 (0) 72 556 68 69, E-mail: dennis.baecklund@integrum.se
Certified Adviser
Erik Penser Bank is Certified Adviser and can be reached at +46 (0) 8-463 8000.